^
    almost2years
    Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion. (PubMed, Invest New Drugs)
    "Moreover, the patient achieved an admirable response to alectinib, with a clinical evaluation of complete response (CR). In summary, our findings expand the spectrum of ALK fusion patterns and provide robust evidence for the precise administration of alectinib in the future."
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay • ZytoLight® SPEC ALK Dual Color Break Apart Probe
    |
    Alecensa (alectinib)